相关实验视频

Updated: Jul 5, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

林德拉皮龙类似物LPD-01通过向进口来作为癌症治疗剂

Takahiro Kitagawa¹, Takahiro Matsumoto², Tomoe Ohta³

¹Laboratory of Public Health, Kyoto Pharmaceutical University, Misasagi, Yamashina-ku, Kyoto, 607-8412, Japan.

Journal of natural medicines

|January 24, 2024

概括

Wnt/β-catenin信号通路抑制剂LPD-01更有效地降低了结直肠癌细胞的生长. LPD-01针对importin7,抑制其核转移和下游Wnt/β-catenin信号传输.

科学领域:

分子生物学分子生物学
癌症研究癌症研究
细胞信号传递细胞信号传递

背景情况:

Wnt/β-catenin信号通路对细胞增殖和发育至关重要,并且与各种癌症有关.
一种新型的小分子抑制剂LPD-01此前已合成并被证明可以抑制人类结直肠癌 (HT-29) 细胞生长.

研究的目的:

调查LPD-01对结直肠癌细胞系 (HT-29与SW480) 的差异性疗效.
在HT-29细胞中识别LPD-01的特定标蛋白.
阐明LPD-01抑制Wnt/β-catenin信号传递的机制.

主要方法:

使用HT-29和SW480细胞进行细胞生长比较试验.
西部斑点分析以评估与Wnt/β-catenin通路相关的蛋白质表达.
化学拉下测定与质谱学相结合,以确定LPD-01结合蛋白.
通过siRNA介导的进口7.in的淘汰.
在TGF-β刺激细胞中分析进口货物 (Smad2,Smad3) 的核转移.

主要成果:

与SW480细胞相比,LPD-01在HT-29细胞中显示出更强的生长抑制.
在不降低β-catenin水平的情况下,LPD-01抑制了Wnt/β-catenin向基因 (c-Myc,Survivin) 的表达.
质谱学确定了importin7作为LPD-01.1的直接结合蛋白.
LPD-01 抑制了进口货物的核转移 (Smad2,Smad3).
进口in7 knockdown 降低了 Wnt/β-catenin 向基因的表达.

结论:

LPD-01抑制了结直肠癌细胞中的Wnt/β-catenin信号通路,可能通过importin7.
鉴定出Importin7是LPD-01的直接标,其抑制影响了Wnt/β-catenin信号传递.
这些发现表明importin7作为结直肠癌治疗的潜在治疗点.

关键词:

在LPD-01中,我们可以使用LPD-01.林德拉皮罗尼 (Linderapyrone) 是一种这是一个可悲的悲伤.在Wnt/β-catenin中使用.在进口7年7月.

更多相关视频

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...